TGFBR2 and neoplasm: By engineering anti-mesothelin CAR-T cells with CRISPR/Cas9 to knockout the TGFBR2, a complete tumor remission was achieved after intratumor or intravenous injection of edited CAR-T cells in the pancreatic tumor PDX mice [54].